{
    "clinical_study": {
        "@rank": "9924", 
        "arm_group": [
            {
                "arm_group_label": "phosphatidylcholine supplementation", 
                "arm_group_type": "Experimental", 
                "description": "phosphatidylcholine concentrate 700 mg twice per day"
            }, 
            {
                "arm_group_label": "placebo supplementation", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo manufactured look like phosphatidylcholine concentrate dosed at 1.2 ml twice per day"
            }
        ], 
        "brief_summary": {
            "textblock": "Sensory gating is defined as the automatic process of inhibiting brain response to repeated\n      auditory sounds. Infants who brains respond similarly to two identical sounds presented\n      about 1/2 second apart are more likely to have later problems with attention than infants\n      who suppress response to the second sound. This study will examine whether providing a\n      nutritional supplement, phosphatidylcholine, for two months in infancy will result in an\n      increased likelihood of developing more robust sensory gating."
        }, 
        "brief_title": "Phosphatidylcholine Supplementation in Infants", 
        "condition": [
            "Schizophrenia", 
            "Diminished P50 Sensory Gating"
        ], 
        "condition_browse": {
            "mesh_term": "Schizophrenia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy infant has an age (adjusted for gestational age at birth) of 1-7 weeks\n\n          -  Diminished P50 sensory gating (ratio greater than or equal to 0.50)\n\n        Exclusion Criteria:\n\n          -  No maternal reported tobacco use for greater than 1 year and no current tobacco use\n             (as measured by urine cotinine levels)\n\n          -  Trimethylaminuria, renal disease, liver disease, known chromosomal abnormality,\n             chronic neurological disorder, premature birth, prenatal exposure to exogenous\n             steroid use"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "7 Weeks", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "162", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01905605", 
            "org_study_id": "13-2182"
        }, 
        "intervention": [
            {
                "arm_group_label": "phosphatidylcholine supplementation", 
                "intervention_name": "phosphatidylcholine supplementation", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "placebo supplementation", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 19, 2014", 
        "link": {
            "description": "University of Colorado School of Medicine Developmental Psychiatry Research Lab", 
            "url": "http://www.ucdenver.edu/academics/colleges/medicalschool/departments/psychiatry/Research/developmentalresearch/Pages/Overview.aspx"
        }, 
        "location": {
            "contact": {
                "email": "amber.americanos@ucdenver.edu", 
                "last_name": "Amber Americanos, RN", 
                "phone": "303-724-6206"
            }, 
            "facility": {
                "address": {
                    "city": "Aurora", 
                    "country": "United States", 
                    "state": "Colorado", 
                    "zip": "80045"
                }, 
                "name": "University of Colorado Denver"
            }, 
            "investigator": {
                "last_name": "Randal G Ross, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phosphatidylcholine Supplementation in Infants With Diminished Sensory Gating", 
        "other_outcome": [
            {
                "measure": "percentage of planned dietary supplement given to the infant", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "serum choline, betaine, and dimethylglycine levels", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }
        ], 
        "overall_contact": {
            "email": "randy.ross@ucdenver.edu", 
            "last_name": "Randal G Ross, MD", 
            "phone": "303-724-6203"
        }, 
        "overall_official": {
            "affiliation": "University of Colorado, Denver", 
            "last_name": "Randal G Ross, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board", 
                "United States: Data and Safety Monitoring Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "September 2023", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "In an auditory evoked potential paradigm while in active sleep (the infant equivalent of rapid eye movement sleep) with two identical sounds presented 500 ms apart, the ratio of the amplitude of the P50 response to the second sound divided by the amplitude of the P50 response to the first sound.", 
            "measure": "P50 auditory sensory gating ratio", 
            "safety_issue": "No", 
            "time_frame": "8 weeks post initiation of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01905605"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Colorado, Denver", 
            "investigator_full_name": "Randy Ross", 
            "investigator_title": "Professor, Department of Psychiatry", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Percentage of infants with adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "4 weeks and 8 weeks after initiation of intervention"
        }, 
        "source": "University of Colorado, Denver", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Colorado, Denver", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}